us cautiou lower tp
solid overal guidanc increas remain
cautiou mid-term outlook report strong top-line beat
yesterday trulic forteo ciali humalog significantli
beat expect convers manag indic
product especi trulic experienc solid volum
growth lower medicaid util favor medicaid price adjust
also contribut out-performance anim health one part
busi notic under-perform potenti increas
likelihood busi eventu divest also rais question
valu would gener near-term transact higher
sg expens mitig much top-line beat lower tax rate
go forward help drive ep estim
target price
blend dcf rel valuat
maintain under-perform rate given challeng see face
especi core diabet busi novo victoza recent label
expans launch novo ozemp upcom phase data
novo oral semaglutid main risk call stronger
expect commerci execut especi key diabet
oncolog product disappoint key competitor novo
pleas let us know would like updat
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
follow-up manag
opportun speak member team follow confer
call gain addit clariti dynam around certain product
well bake expect around fy summar
compani answer question
lower medicaid util expect turn benefit across
part portfolio
favor net price adjust also seen result
benefit inventori tough quantifi given well product
could also normal year-end dynam
vast major growth volum
ex-u opportun start pick
sale come pcp
patient popul lower lower shorter diseas durat
leader trial diabet year rewind
feel give broader real-world popul
comfort power
primari endpoint studi power superior
benefit medicaid adjust quantifi
also benefit volum due stock
fy number reflect underli trend
favor medicaid adjust help well
favor medicaid adjust similar size shouldnt impact yoy
growth rate impact absolut number
look number quarter get better sens dynam product
us mid-singl digit declin volum flat slightli declin due
see impact viagra gener expect appar much
cs expect
quarter major downsid posilac market access issu year long
less sale look option busi includ
companion anim flea/tick opportun market dynam endo vs ecto
gap portfolio
credelio cover ecto help off-set declin trifexi
tripl combo flea/tick/heartworm work comment
top prioriti remain invest current busi
on-going project constrain due tax chang
use repatri dollar reduc debt level
year schedul first
save announc still expect
reinvest back busi
charg seen total
primarili due restructur earli retir
sale
sale
us million unless otherwis state
sale
total incom expens
provis incom tax
us million unless otherwis state
equival
prepaid expens current asset
properti equip net
accum comp expens treasuri stock
equiti attribut non-control interest
total liabil sharehold equiti
us million unless otherwis state
us million unless otherwis state
galcanezumab migrain headach
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
price feb rate under-perform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
abemaciclib olaratumab compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale trulic
olaratumab compar current base case assumpt
grey sky valuat base dcf driven wacc
compani mention price
